Iovance Biotherapeutics (IOVA) Other Accumulated Expenses (2012 - 2024)

Iovance Biotherapeutics (IOVA) has reported Other Accumulated Expenses for 8 consecutive years, with $4.0 million the latest figure, recorded in Q1 2024.

• In Q1 2024, Other Accumulated Expenses fell 7.25% year-over-year to $4.0 million; the TTM figure through Mar 2024 stood at $4.0 million (down 7.25% YoY), while the FY2023 annual figure was $6.6 million, up 99.61% from the prior year.
• Other Accumulated Expenses declined to $4.0 million in Q1 2024 per IOVA's latest filing, from $6.6 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $6.6 million in Q4 2023 and bottomed at $1.7 million in Q1 2020.
• Historically, Other Accumulated Expenses has averaged $3.3 million across 5 years, with a median of $3.3 million in 2022.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses surged 128.64% — and 2023, when it decreased 20.78%.
• Iovance Biotherapeutics' Other Accumulated Expenses stood at $1.7 million in 2020, then surged by 119.39% to $3.8 million in 2021, then dropped by 12.06% to $3.3 million in 2022, then jumped by 99.61% to $6.6 million in 2023, then tumbled by 39.65% to $4.0 million in 2024.
• Business Quant data shows IOVA's Other Accumulated Expenses at $4.0 million in Q1 2024, $6.6 million in Q4 2023, and $4.3 million in Q3 2023.